ONASCO BIOTECHNOLOGIES DEVELOPS FIVE NEW VACCINES
ONASCO BIOTECHNOLOGIES DEVELOPS FIVE NEW VACCINES HOUSTON, June 26 /PRNewswire/ -- ONASCO Biotechnologies, Inc.
today announced the development and manufacture of five new synthetic vaccines. These vaccines, prepared for research purposes only, include: 1) Poliovirus vaccine; 2) Human T-Lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) vaccine; 3) Spumavirus vaccine; 4) Type D retrovirus vaccine; and 5) A vaccine against most known retroviruses (RETROVAX), except HIV-1 and HIV-2. Extensive efficacy testing will be required for FDA approval and no assurance can be given as to the efficacy of these products nor to FDA approval.
Recent theories of potential contamination of the monkey kidney cells, which are used to make poliovirus vaccines in the United States, prompted ONASCO to develop a totally synthetic poliovirus vaccine. The estimated U.S. market for poliovirus vaccines is $100 million per year. ONASCO hopes to capture a significant portion of this market upon successful completion of efficacy testing and FDA approval. ONASCO decided to manufacture small quantities of totally synthetic vaccines to other human and monkey retroviruses, besides HIV-1 and HIV-2, which include: 1) The human T-lymphotropic retrovirus types 1 and 2 (HTLV-1 and HTLV-2), which have been associated with certain diseases and are endemic in Japan; 2) The spumavirus (foamy virus), which has been isolated from both humans and monkeys; 3) The type D retrovirus, which causes most of the simian AIDS (SAIDS) in captive monkeys and has recently been isolated from a human with AIDS; and 4) a vaccine against many known retroviruses (RETROVAX), which includes HTLV-1, HTLV-2, spumavirus, and type D retroviruses. The company estimates that a multi-billion dollar market exists for these products worldwide, but is quick to point out that extensive efficacy testing must be done as well as FDA approval received before these vaccines are made available to the public. No assurance can be given that these products will prove to be effective or that FDA approval will be granted. ONASCO Biotechnologies, Inc. is a wholly owned subsidiary of ONASCO Companies, Inc., a publicly held corporation traded Over-The-Counter (OTC) on the NASD electronic bulletin board system (OBIO). -0- 6/26/92 /CONTACT: Dr. Robert Bohannon of ONASCO Biotechnologies, 713-498-0779 or (fax) 713-933-0922/ (OBIO) CO: ONASCO Biotechnologies Inc. ST: Texas IN: MTC SU: PDT
TS -- NY041 -- 4226 06/26/92 12:42 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 26, 1992|
|Previous Article:||FIRST FEDERAL SAVINGS BANK OF NEW SMYRNA ANNOUNCES DIVIDEND|
|Next Article:||ULTRAMAR ANNOUNCES INITIAL PUBLIC OFFERING|